BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
JFK's granddaughter Tatiana Schlossberg reveals terminal cancer diagnosis - 2Online business Stages for Little Retailers
- 3Flu cases skyrocket in US. See cases, where people got sick.
- 4Top 15 Online Entertainment Stages for Individual Marking
- 5Palestinians reel under winter rains as Israel blocks Gaza shelter supplies
- Manual for Picking Coastline Travel
- Dark matter may be made of pieces of giant, exotic objects — and astronomers think they know how to look for them
- Full Supreme Court to hear challenge to Judicial Selection Committee law
- Vote In favor of Your Favored Web based Dating Application
- Find the Specialty of Calligraphy: Dominating the Exquisite Art of Penmanship
- Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- Is Trump going to war with Venezuela?
- Dominating Capable Mastercard Utilization: Key Contemplations
